After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Sutro Biopharma Inc is $293.17M. A total of 1.23 million shares were traded on the day, compared to an average of 894.49K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, STRO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 26 BUYs and 20 SELLs from insiders. Insiders purchased 285,107 shares during that period but sold 127,355.
In the most recent transaction, Shtylla Brunilda sold 15,428 shares of STRO for 4.71 per share on Aug 28. After the transaction, the Chief Business Officer now owns 0 company shares. In a previous transaction on Aug 25, Shtylla Brunilda sold 11,613 shares at 4.59 per share. STRO shares that Chief Business Officer owns now total 12,928.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for STRO in the last 3 months, the mean price target is $13.38 with high estimates of $20.00 and low estimates of $8.00. In terms of 52-week highs and lows, STRO has a high of $7.92 and a low of $2.01.
As of this writing, STRO has an earnings estimate of -$0.82 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$0.94. The company reported an EPS of -$0.64 in the last quarter, which was 12.30% higher than expectations of -$0.73.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. STRO’s latest balance sheet shows that the firm has $197.94M in Cash & Short Term Investments as of fiscal 2021. There were $57.37M in debt and $41.74M in liabilities at the time. Its Book Value Per Share was $1.84, while its Total Shareholder’s Equity was $252.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for STRO is Buy with a score of 4.80.
